Is Avatrombopag on the market?

Avatrombopag was approved by the U.S. Food and Drug Administration (FDA) in May 2018 for the treatment of thrombocytopenia (low platelets) in adults with chronic liver disease who are scheduled to undergo surgery. It is administered orally as atrombopag maleate salt and is marketed under the trade name Doptelet. The European Medicines Agency decided that the benefits of avatrombopag outweighed the risks, and it was approved in the EU in June 2019 and in Australia in January 2023. Avatrombopag The original drug was approved by the State Food and Drug Administration in April 2020, with the trade name Su Kexin.